DiaPat-CoV-50-Test + Heart failure and coronary heart disease Test
The DiaPat-CoV-50-Test or Test-Combination is currantly only availible in Germany under the conditions described below.
DiaPat-CoV-50 test, molecular detection of the course of complications of a Covid-19 disease.
The test is only for patients with a proven SARS-CoV-2 infection. Inclusion criterion is a positive PCR result. Exclusion criteria are urinary tract infection or symptom nephrolitiasis.
The test will be sent to your doctor or you immediately, according to your instructions, and you and your doctor will find out where and when the urine will be given.
In view of the legal situation for in-vitro diagnostics of the EU directive, all DiaPat tests, such as urine output, are only to be carried out under the instruction of a doctor and the patient is only to be given the diagnostic results by him. The urine sample taken is then sent to us for analysis.
The results will then be sent to your treating doctor, with whom you can clarify any further measures that may be necessary.
The DiaPat-CoV-50 test costs 850 euros.
The DiaPat-CoV-50 test has received the approval!
Patients who have tested positive for Covid-19 with a PCR test can now determine at an early stage whether they are facing a serious course, which they can prevent with timely medication. The patients concerned can obtain the simple DiaPat-CoV-50 test from urine directly from their family doctor or their local clinic.
The DiaPat-CoV-50 test is currently not reimbursed by the federal government and is not included in the payment catalog of the statutory health insurance companies. To the best of our knowledge, there is no DRG to avoid serious disease progression in Covid-19 patients, which the clinics can bill.
The early - prognostic - detection of the complication course of Covid 19 by the DiaPat-CoV-50 test enables the timely use of medication and prevents intensive medical treatment and the use of ventilators - saves lives and eliminates the need for lockdown measures!
Once a Covid-19 disease has been identified, it can be determined whether the patient has a
- light (WHO grade 1-3 - no inpatient stay, no ventilation requirement)
- severe (WHO grade 4-5 - inpatient surveillance, no intensive care measures yet)
- very severe (WHO grade 6 - intensive care measures, mechanical ventilation if necessary)
Course and can thus receive various therapeutic agents in good time to prevent severe courses and thus save lives.
All studies to date show the benefits of therapeutic use in the early phase of Covid-19. Only then is the individualized dosage and coordination of the different medicinal effects possible efficiently. This results from the mechanism of action of the drugs alone:
- either: reduction of the viral load
- or: Reduction of the excessive immune reaction
If there is organ damage caused by an uncontrolled Covid-19 disease, it can no longer be "repaired". Therapy would come too late. If previous damage by the endothelium in the organ vessels due to chronic cardiovascular and kidney diseases is not recognized and therefore not taken into account, the prognosis of the course of Covid-19 is all the more urgent. An overview of the individual therapeutic effects and limitations Remdesivir and in particular antibodies against SARS-CoV-2 are only available to a limited extent and have significant side effects. Prophylactically, these therapeutics cannot be administered to all patients with Covid-19. Antibodies are effective, but hardly available therapeutics. Steroids are effective in the early stages, but have significant side effects. The compromise of the immune system also favors secondary infections, which is why steroids may only be used in a targeted manner.
Information about the DiaPat-CoV-50 test
As part of the Crit Cov study funded by the BMG, a test based on 50 urine peptides, DiaPat-CoV-50, was developed, which shows a critical (WHO grade 6 or higher) course of Covid-19 disease with high significance [82.6% Sensitivity (95% CI (67.1-98.1%) with 86.2% specificity (95% CI (81.1-91.3)%]). This supports the possibility of an early targeted preventive therapy. The test is only for patients with a proven SARS-CoV-2 infection. Inclusion criterion is a positive PCR result. Exclusion criteria are urinary tract infection and symptom nephrolitiasis.
Molecular, early detection of heart failure and coronary heart disease
DiaPat Heart failure and coronary heart disease Test, (DiaPat-HF1-85/HF2-710/DiaPat-CAD238)
Please also read our Product data sheet and the recommendations/instructions at the end of this page.
The DiaPat Heart failure and coronary heart disease Test is a test in urine that predicts the risk of heart failure caused by calcified arteries (arteriosclerosis). Before the first clinical symptoms occur, the DiaPat Heart failure and coronary heart disease Test very reliably detects even the smallest, not yet visible plaque deposits by analyzing 238 arteriosclerosis-specific proteins. The test is currently the only diagnostic tool available to detect plaques at this early stage. Based on these test characteristics, the DiaPat Heart failure and coronary heart disease Test ensures timely diagnosis and significantly improves the success of therapy so that heart attack and ischemic stroke can be prevented. The DiaPat Heart failure and coronary heart disease Test is a clinically validated valuable method for early detection and subsequent therapy guidance.
Instructions for use
For the DiaPat® test, the midstream of second morning urine is collected in a urine cup. The urine is then transferred to the enclosed urine monovette (sample syringe) *. The urine monovette is placed in protective packaging* for transport. Transport to the laboratory will be carried out per overnight express (see also instructions for use).
*These materials will be provided as part of the DiaPat® sample collection kit
The DiaPat Heart failure and coronary heart disease Test includes the following services:
The DiaPat® package includes the sample set for collecting the urine sample and all the necessary documents. The shipment will be operated by a courier by home pickup or via the doctor's office.
The analysis will be conducted in our central laboratory using the CE-MS technology.
Medical history questionnaire form
A detailed medical history questionnaire is part of the sampling kit. Please fill it out carefully and completely. The information is the basis for a reliable evaluation of the DiaPat® test result.
Send the result letter to your family doctor
The result of the protein analysis, which we send to your doctor, is explained in detail and gives recommendations for further diagnostic steps.